[PRNewswire] PharmaZell and Novasep enter into exclusive negotiations in new
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
drive to create a technology-driven leader for complex small molecules and ADCs of global scale
(RAUBLING, Germany and LYON, France, Sept. 16, 2021 PRNewswire=연합뉴스) PharmaZell, the German producer of highly resilient and specialty APIs, and France-based Novasep, a leading CDMO focused on complex small molecules and ADCs have entered into exclusive negotiations to create a leading European platform in the attractive API manufacturing and CDMO space with a complementary set of differentiated technologies and highly diversified base of blue-chip pharma and biotech customers.
Novasep is a leading CDMO player developing and manufacturing complex small molecules predominantly for pharma and biotech customers. The company leverages a wide range of differentiated technologies including high energy and cryogenic chemistries and industrial scale chromatography. It is a world leader in ADC and HPAPI, fast-growing targeted cancer therapy segments.
Novasep's capabilities are highly complementary to PharmaZell's expertise in the manufacturing of complex APIs requiring special handling procedures or technologies. Combining the two businesses would create a leading, highly diversified, and highly differentiated API manufacturing and CDMO platform. The combined business would be able to draw from a comprehensive and broad technology suite for complex molecules and a global production footprint to support pharma and biotech customers over the complete lifecycle of a drug. The combined business would generate nearly €500m of revenues and employ close to 2,000 employees across seven production and R&D sites in Europe (Germany, France and Italy), two sites in India and one in the US.
The proposed transaction would be backed by PharmaZell's current majority shareholder Bridgepoint. Bridgepoint Group PLC is the world's leading quoted private assets growth investor focused on the middle-market with €27 billion AUM and a local presence in the US, Europe and China.
The proposed acquisition remains subject to the fulfilment of customary conditions precedent for this type of transaction including the information and consultation of works councils and other regulatory approvals.
The Press release is available in pdf.
Photo - https://mma.prnewswire.com/media/1628012/Novasep_PharmaZell.jpg
PR PharmaZell Novasep
Logo - https://mma.prnewswire.com/media/1628011/Novasep_Passion_Smart_Processes_Logo.jpg
Novasep_Passion_Smart_Processes_Logo
PDF - https://mma.prnewswire.com/media/1628027/PharmaZell_Novasep_ENG.pdf
Contact details:
press@novasep.com
Source: Novasep
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 헌재 "유산상속 강제하는 '유류분', 위헌·헌법불합치" 결정(종합) | 연합뉴스
- "구체적 의대정원 논의 없다…의료인력 장기수급은 논의 가능"(종합) | 연합뉴스
- 尹·李회담 의제 조율 난항…두차례 실무회동서 빈손(종합) | 연합뉴스
- 대통령실 "민간주도 역동적 성장 복귀…성장률 2.2% 넘어설 것" | 연합뉴스
- 민희진 "하이브가 나를 배신…실컷 뽑아 먹고 찍어누르려 해"(종합) | 연합뉴스
- '노동자 월평균 근무일' 22일→20일…대법 21년만에 기준변경 | 연합뉴스
- 고부가車 앞세운 현대차, 1분기 40.6조 최대매출…실적호조 행진(종합) | 연합뉴스
- 與토론회서 쓴소리 분출…"사람들 죽겠다는데 수출 잘된단 얘기만"(종합) | 연합뉴스
- 검찰, 전준경 전 민주연구원 부원장 기소…8억대 금품수수 혐의(종합2보) | 연합뉴스
- 이복현 "금투세 유예는 비겁한 결정…공매도 재개시점 단정불가" | 연합뉴스